Report: Obesity therapy market forecast to reach $8.4 billion by 2022

Due to the launches of several novel drugs during the next decade, the obesity therapeutics market will increase from a value of just $407 million in 2012 to $8.4 billion by 2022, expanding at a compound annual growth rate (CAGR) of 35.3%, forecasts research and consulting firm GlobalData.

The company’s latest report states that the USA, Canada and Japan will have the largest obesity therapy sales by 2022, with shares of $5.3 billion, $702 million and $484 million, respectively.

Rebecca Wong, GlobalData’s analyst covering cardiovascular and metabolic disorders, says: “The obesity space has seen little activity in the past decade due to a pharmacological history of modest efficacy, poor tolerability with dangerous side effects, and limited healthcare coverage, which have all contributed to the commercial failure of anti-obesity drugs. Recently, however, there has been a revival of this market space, as a couple of companies have released drugs that challenge these limitations.”